Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978120 | 0.85 | CYP4F2 (0.33) | CYP4F2CYP4A11DGAT1MEN1KMT2A | |
| SCHEMBL22498769 | 0.82 | ALDH1A1 (0.38) | ALDH1A1CYP4F2CYP4A11CHRNB2CHRNB4 | |
| SCHEMBL2022397 | 0.78 | DGAT1 (0.44) | ALDH1A1CYP4F2CYP4A11DGAT1TSHR | |
| SCHEMBL10046557 | 0.77 | ALDH1A1 (0.43) | ALDH1A1CHRNB2CHRNB4CHRNA4TSHR | |
| SCHEMBL5911694 | 0.77 | ALDH1A1 (0.39) | ALDH1A1CYP4F2CYP4A11DGAT1TSHR | |
| SCHEMBL759137 | 0.77 | TSHR (0.52) | ALDH1A1CYP4F2CYP4A11DGAT1MEN1 | |
| SCHEMBL3283628 | 0.77 | DGAT1 (0.37) | CYP4F2CYP4A11DGAT1TSHR | |
| SCHEMBL161711 | 0.77 | NAALAD2 (0.45) | ALDH1A1CYP4F2CYP4A11DGAT1MEN1 | |
| SCHEMBL8236215 | 0.75 | CYP4F2 (0.33) | CYP4F2CYP4A11 | |
| SCHEMBL22842728 | 0.75 | ALDH1A1 (0.41) | ALDH1A1CHRNB2CHRNB4CHRNA4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648858-B1 | METHOD FOR PRODUCTION OF ALPHA, BETA-UNSATURATED AMIDE COMPOUNDS | SIEGFRIED GENERICS INT AG (CH) | 2008-07-02 | — | — | EP | disclosed |
| US-20060281949-A1 | Method for production $g(a),$g(b)-unsaturated amide compounds | SIEGFRIED GENERICS INTERNATIONAL AG (CH) | 2006-12-14 | — | — | US | disclosed |
| EP-1648858-A1 | METHOD FOR PRODUCTION OF ALPHA, BETA-UNSATURATED AMIDE COMPOUNDS | Siegfried Generics International AG (CH) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005007618-A1 | METHOD FOR PRODUCTION OF $G(A),$G(B)-UNSATURATED AMIDE COMPOUNDS | SIEGFRIED GENERICS INTERNATIONAL AG (CH) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281949-A1 | Method for production $g(a),$g(b)-unsaturated amide compounds | GSTA2, GSTO1, GLB1 | ALDH1A1 218/4885CYP4F2 785/4885CYP4A11 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.